Normocalcaemic hyperparathyroidism and primary hyperparathyroidism: least significant change for adjusted serum calcium
- PMID: 33112283
- PMCID: PMC7707804
- DOI: 10.1530/EJE-20-0634
Normocalcaemic hyperparathyroidism and primary hyperparathyroidism: least significant change for adjusted serum calcium
Abstract
Introduction: The least significant change (LSC) is a term used in individuals in order to evaluate whether one measurement has changed significantly from the previous one. It is widely used when assessing bone mineral density (BMD) scans. To the best of our knowledge, there no such estimate available in the literature for patients with disorders of calcium metabolism. Our aim was to provide an estimate of the least significant change for albumin-adjusted calcium in patients with normocalcaemic hyperparathyroidism (NPHPT) and primary hyperparathyroidism (PHPT).
Methods: We used the within-subject standard deviatio calculated in a population of NPHPT and PHPT patients and multiplied it by 2.77.
Results: The LSC for NPHPT and PHPT were found to be 0.25 and 0.24 mmol/L, respectively (1.00 and 0.96 mg/dL). In clinical practice, the value of 0.25 mmol/L could be used.
Discussion: The least significant change given, could be used in two ways in these patients. First, it gives a range to which values are expected. This can provide some reassurance for the patient and the physician in cases of intermittent hypercalcaemia. Moreover, it can be a marker of whether an individual has an actual significant change of his calcium after parathyroid surgery.
Figures


Similar articles
-
Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History.J Clin Endocrinol Metab. 2020 Apr 1;105(4):e1171-86. doi: 10.1210/clinem/dgaa084. J Clin Endocrinol Metab. 2020. PMID: 32072184 Free PMC article.
-
Biochemical characteristics and clinical manifestation of normocalcemic primary hyperparathyroidism.Endocrine. 2024 Jul;85(1):341-346. doi: 10.1007/s12020-024-03768-6. Epub 2024 Mar 15. Endocrine. 2024. PMID: 38489132
-
Normocalcemic Primary Hyperparathyroidism: A Comparison with the Hypercalcemic Form in a Tertiary Referral Population.Horm Metab Res. 2018 Nov;50(11):797-802. doi: 10.1055/a-0752-4533. Epub 2018 Nov 5. Horm Metab Res. 2018. PMID: 30396209
-
Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm.Langenbecks Arch Surg. 2017 Nov;402(7):1103-1108. doi: 10.1007/s00423-017-1617-2. Epub 2017 Aug 19. Langenbecks Arch Surg. 2017. PMID: 28823005 Review.
-
Normocalcemic primary hyperparathyroidism: From pathophysiology to clinical management.Am J Surg. 2024 Sep;235:115812. doi: 10.1016/j.amjsurg.2024.115812. Epub 2024 Jun 26. Am J Surg. 2024. PMID: 39002253 Review.
Cited by
-
Normocalcemic Primary Hyperparathyroidism: Need for a Standardized Clinical Approach.Endocrinol Metab (Seoul). 2021 Jun;36(3):525-535. doi: 10.3803/EnM.2021.1061. Epub 2021 Jun 1. Endocrinol Metab (Seoul). 2021. PMID: 34107603 Free PMC article. Review.
-
Osteoporosis and Normocalcemic Primary Hyperparathyroidism (Conservatively or Surgically Managed).J Clin Med. 2024 Oct 23;13(21):6325. doi: 10.3390/jcm13216325. J Clin Med. 2024. PMID: 39518465 Free PMC article. Review.
References
-
- Eastell R, Arnold A, Brandi ML, Brown EM, D’Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ.et al 2009. Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop (in Eng). Journal of Clinical Endocrinology and Metabolism 94 340–35. (10.1210/jc.2008-1758) - DOI - PubMed
-
- Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, Dempster D, Lewiecki EM, Liu JM, Minisola S.et al Current issues in the presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop (in Eng). Journal of Clinical Endocrinology and Metabolism 2014. 99 3580–35. (10.1210/jc.2014-1415) - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources